Book Value per Share: Aadi Bio (AADI)

Aadi Bioscience does not pay dividends, instead investing in strict temperature control during drug transportation. The bps metric serves as an indicator of confidence in management, where the 2.82 mark reflects the latest data. High R&D costs and FDA oversight create significant barriers, and the success of Aadi Bioscience depends on winning the race for leadership in the rare sarcoma therapy niche.

This indicator serves as a key filter during portfolio stress testing, determining the level of assets' intrinsic value per share. It reflects the company's residual capital net of liabilities, which allows for an assessment of the financial stability of Aadi Bioscience (AADI) through the current book value per share, underpinned by its monopoly right to a rare cancer therapy and the long-term potential for patent commercialization.